龙津药业(002750) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥65,213,290.42, a decrease of 21.29% compared to ¥82,849,713.12 in the same period last year[8] - Net profit attributable to shareholders was ¥5,237,314.30, down 27.68% from ¥7,242,158.75 year-on-year[8] - Basic and diluted earnings per share were both ¥0.0131, representing a decrease of 27.62% from ¥0.0181 in the same period last year[8] - Total operating revenue for Q1 2019 was CNY 65,213,290.42, a decrease from CNY 82,849,713.12 in the previous period[35] - Net profit for Q1 2019 was CNY 5,211,016.89, compared to CNY 7,242,158.75 in the same period last year, representing a decline of approximately 28.1%[37] - The net profit for the current period is CNY 5,359,751.12, down 27.2% from CNY 7,362,282.03 in the previous period[41] - The total comprehensive income for the current period is CNY 5,359,751.12, down from CNY 7,362,282.03 in the previous period[42] Cash Flow - The net cash flow from operating activities was negative at -¥6,357,138.88, a decline of 156.04% compared to ¥11,343,297.64 in the previous year[8] - The cash flow from operating activities shows a net outflow of CNY 6,357,138.88, compared to a net inflow of CNY 11,343,297.64 in the previous period[45] - The net cash flow from operating activities was -6,421,890.02 CNY, a decrease from 11,340,262.34 CNY in the previous year[49] - The total cash outflow from investing activities is CNY 23,144,444.00, compared to CNY 416,702,339.70 in the previous period, showing a decrease in investment outflows[46] - Total cash inflow from investment activities was 378,820,013.70 CNY, while cash outflow was 23,144,444.00 CNY, resulting in a net cash flow of -23,144,444.00 CNY[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥770,549,754.51, down 2.16% from ¥787,549,742.85 at the end of the previous year[8] - The total assets decreased to ¥770,549,754.51 from ¥787,549,742.85, indicating a decline in overall asset value[27] - Total liabilities decreased to ¥109,405,790.29 from ¥131,616,795.52, showing a reduction in the company's obligations[28] - Total assets as of March 31, 2019, were CNY 762,875,836.19, a decrease from CNY 779,375,393.53 at the end of 2018[34] - Total liabilities as of March 31, 2019, were CNY 109,644,745.56, down from CNY 131,504,054.02 at the end of 2018[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,562[11] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., held 43.82% of the shares, amounting to 175,500,000 shares[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] Research and Development - R&D expenses increased by 37.54% to ¥3,123,409.80, reflecting ongoing investments in product development and new drug research[16] - Research and development expenses for Q1 2019 were CNY 3,123,409.80, an increase from CNY 2,270,890.30 in the previous period[35] - The company reported a significant increase in R&D expenses, which rose to CNY 3,123,409.80 from CNY 2,270,890.30, marking an increase of 37.6%[40] Financial Adjustments and Reporting - The company has adjusted its financial statements according to new financial instrument standards, impacting the classification of certain assets[57] - The financial report has not been audited, which may affect the reliability of the reported figures[58] - The company has not disclosed any new product developments or market expansion strategies in this report[58] Other Financial Metrics - Non-recurring gains and losses totaled ¥574,772.07, with government subsidies contributing ¥405,282.30[9] - The company reported a 195.63% increase in income tax expenses to ¥1,895,828.23, influenced by changes in deferred tax assets and R&D expense deductions[16] - Investment income fell by 205.24% to -¥726,351.51, due to variations in financial product holdings and increased losses from equity method investments[16] - The company incurred a financial expense of CNY -2,992,236.00, compared to CNY -319,602.43 in the previous period, indicating a significant increase in financial costs[40] - The company reported a decrease in cash flow from operating activities, indicating potential challenges in operational efficiency[49]